ArticleBioactive materials2026
Small patients - Big needs: A material-based approach to develop miniaturised valves for congenital heart diseases.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatric valve replacements cannot be built by simply scaling down bigger-sized valve implants. Innovative approaches that combine novel material systems, processing technologies, and device designs are needed to develop adaptable, durable, and biocompatible miniaturised solutions tailored to the paediatric population with congenital heart diseases. In response to that medical need, in this work, we have developed miniaturised valves following a biohybrid approach that combines synthetic components with bioinspired materials to exploit the optimal properties of each. Specifically, the valve was composed of (i) an electrospun synthetic polymer to provide stability, (ii) protein-engineered elastin to ensure flexibility and low thrombogenicity, and (iii) a tailor-made stent to enable minimally invasive implantation. Our valve implant demonstrated outstanding maximum strain values over 300 %, maximum stresses exceeding 6 MPa, and the ability to withstand burst pressures over 1000 mmHg. Blood compatibility tests revealed lower platelet activation than ePTFE, which is a material used in clinical applications. The hydrodynamics of the miniaturised valve met the standards outlined in the ISO guidelines with regurgitation fractions below 15 % and complete valve closure, indicating excellent functionality. Overall, we have established a material-based approach to address the clinical demand for small valves for children suffering from congenital heart diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.